Investigation of doxorubicin combined with ciprofloxacin-induced cardiotoxicity: from molecular mechanism to fundamental heart function

BUKHARI A., Eyileten C., Postula M., Tanoglu E. G., KARATAŞ Ö. F., Basci A. B., ...Daha Fazla

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, cilt.396, sa.7, ss.1547-1561, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 396 Sayı: 7
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1007/s00210-022-02331-2
  • Dergi Adı: NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, Chimica, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.1547-1561
  • Anahtar Kelimeler: Cardiotoxicity, Langendorff technique, Cardiac function, CYP2J3, CYP3A1, CYP1A2, Doxorubicin, Ciprofloxacin, ARACHIDONIC-ACID METABOLISM, CARDIAC TROPONIN-I, GENE-EXPRESSION, CYTOCHROME-P450 ENZYMES, ANTIBIOTICS INHIBIT, OXIDATIVE STRESS, RAT, INJURY, MODEL, PROTECTION
  • İstanbul Üniversitesi Adresli: Evet

Özet

This study was designed to investigate the impacts of Doxo alone and in combination with Cipro on the hepatic and cardiac CYP1A2, CYP2J3, and CYP3A1 mRNA levels. We also aimed to analyze the cardiac function by perfusing isolated rat hearts. Rats were given Doxo and/or Cipro in chronic (3-week) and acute (single-day) dosing schedules. Cardiac CYP2J3, CYP3A1, and CYP1A2 gene expression levels were measured by quantitative reverse transcription PCR. Cardiac functions of the isolated hearts were evaluated by using the Langendorff technique. Doxo alone (2.5 mg/kg) and Doxo +Cipro (2.5 mg +20 mg/kg) significantly decreased hepatic CYP1A2 expression compared to saline, whereas Doxo (2.5 mg/kg) and Doxo +Cipro (2.5 mg +20 mg/kg) showed significantly higher cardiac CYP1A2 expression in comparison to control. In the liver tissue, Doxo (2.5 mg/kg) and Doxo +Cipro (2.5 +20 mg/kg) decreased the CYP2J3 expression than the control group. The Doxo (2.5 mg/kg) and Doxo +Cipro (2.5 +20 mg/kg)-treated group had significantly higher cardiac CYP2J3 expression compared to control. Doxo (2.5 mg/kg; cumulative dose 15 mg/kg) and Doxo +Cipro (2.5 +20 mg/kg) showed significantly higher cardiac CYP3A1 expressions than the control. Rate-pressure product (HR xLVDP)/1000) showed an overall decrease in cardiac functions of Doxo (2.5 mg/kg) and Doxo +Cipro (2.5 +20 mg/kg)-treated group. We found considerable effects in chronic protocol; Doxo alone high dose and plus Cipro decreased hepatic CYP1A2 and CYP2J3 mRNA. On the other hand, these treatment groups exhibited an increase in the cardiac CYP1A2, CYP2J3, and CYP3A1 expression and likewise deteriorated the overall hemodynamic parameters.